discontinuing glp 1 Most adults with overweight or obesity discontinue GLP-1 therapy within 2 years Heart Benefits of GLP-1s Disappear

Also, Sanofi Pasteur/GSK, Vaxine, Johnson & Johnson and the University of Pittsburgh have announced that they expect to begin Phase I clinical trials within the next few months

Recent results from the FLOW trial (2024) further revealed that semaglutide can help slow kidney disease progression and reduce the risk of end-stage kidney disease in patients with type 2 diabetes and chronic kidney disease

Statistical analyses were performed using GraphPad Prism (version 9.5.1, GraphPad Software), with statistical tests, comparisons, exact P values, and data exclusion criteria for all experiments provided in Supplementary Data 1

Am J Med 2006;119:591-9.ArticlePubMed 10